Biosimilars

ERIC advocates for a competitive marketplace that includes safe and effective biosimilar medications available without additional burdens imposed on employers, physicians, or pharmacists.

A biosimilar “is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product,” according to the Food and Drug Administration (FDA). Biosimilars are generally priced lower than biologics, and they have the potential to increase competition and bring down pharmaceutical costs.

States are regulating the availability of biosimilars and biologics in a variety of ways that impact employers’ ability to offer affordable prescription drug benefits to their employees. ERIC works against state and local barriers to the availability of safe, effective, and affordable biosimilar medications.

Click here to access ERIC’s State Mandate Action Portal for real time legislative and regulatory reports.

Latest News